Obesity_Care_Clinic .’s Post

This article compares bariatric surgery and emerging medication treatments for obesity, discussing their benefits, risks, and the need for personalized treatment plans. For more insights, read the article here: https://lnkd.in/dUFZYK4F #BariatricSurgery #MedicationTreatments #ObesityManagement #PersonalizedCare #WeightLoss #HealthRisks #NonInvasiveOptions #TreatmentComparison #PatientCare #MedicalAdvancements

In a world where healthcare costs are ever-rising, ASMBS highlights the economic and health benefits of bariatric surgery. With insurers revisiting policies around the treatment of obesity, it's clear: metabolic and bariatric surgery is not just about weight loss; it's a cost-effective, life-changing intervention to a chronic disease. Let's embrace a healthier future together. #ASMBS #ASMBS2024 #insurancecoverage #GLP

Patients with obesity and renal dysfunction may now be eligible for kidney transplants The study, conducted between January 2019 and June 2023, followed 183 ESRD patients referred for bariatric surgery, with 36 undergoing weight loss surgery and 10 subsequently receiving kidney transplants. Results showed a 27% reduction in average BMI at the time of transplant, alongside improvements in hypertension and diabetes management. This improvement in the management of comorbid conditions enhanced patients' overall health and transplant viability. #Obesityandrenaldysfunction | #Kidneytransplants | #Patientsoverallhealth | #Hypertensionanddiabetesmanagement | #Healthnews Read more:

JAMA-published study finds minimally invasive endoscopic sleeve surgery sustained greater weight loss over 5 years and was more more cost-effective than semaglutide (GLP-1 agonist) therapy. Authors conclude that semaglutide list price would have to drop by about 75% to be considered similarly cost-effective. it would be important in this context to know the average #net price of the drug therapies. #weightloss #bariatric

Discover how bariatric surgery can help manage asthma triggers in obese patients. Learn about the connection between obesity and asthma, and how weight management can improve respiratory health and quality of life. https://lnkd.in/eZeJus7j #bariatricsurgery #bariatricireland #asthma

Ovivo this completely contradicts your comment saying Ovivo must be the go to for GPs...how do they refer when most have no access to tier 3 anyways . please can you also answer my question. Who is paying for this 2 Yr programme?

Bariatric surgery ftw? "The model found that Endoscopic sleeve gastroplasty (ESG) was more cost-effective than semaglutide over a 5-year time horizon, with an ICER of –$595 532/QALY. Endoscopic sleeve gastroplasty added 0.06 QALYs and reduced total cost by $33 583 relative to semaglutide. The results remained robust on 1-way and probabilistic sensitivity analyses. Endoscopic sleeve gastroplasty sustained greater weight loss over 5 years vs semaglutide (BMI of 31.7 vs 33.0). *To achieve nondominance, the annual price of semaglutide, currently $13 618, would need to be $3591.* This study suggests that ESG is cost saving compared with semaglutide in the treatment of class II obesity. On price threshold analyses, a 3-fold decrease in the price of semaglutide is needed to achieve nondominance."

A fascinating discussion on the evolving landscape of obesity treatment! While new anti-obesity drugs show remarkable potential, the proven long-term benefits of bariatric (metabolic) surgery remain invaluable. It's clear that both approaches will continue to shape the future of metabolic disease management. Collaboration and innovation will be key in optimizing outcomes for patients. #ObesityTreatment #MetabolicSurgery #InnovationInHealthcare

Miriam E. Tucker at Medscape suggests ‘GLP-1 Costs May Ease Restrictions to Bariatric Surgery.’ For example, Geisinger Health of Pennsylvania and Blue Cross Blue Shield of Massachusetts expanded BMI eligibility for bariatric surgery procedures, while Blue Cross Blue Shield of Michigan dropped prior authorization requirements. This may be in response to the high costs of GLP-1 medications, and a lack of data on cost-effectiveness. However, Dr. Christopher Still at Geisinger Medical Center said ‘…Geisinger Health Plan's change in May 2023 to lower the BMI surgery eligibility cutoff from 35 to 30 for people with comorbidities was not related to the cost of GLP-1 drugs…’ and more focused upon the effective and enduring treatment of obesity and its co-morbidities. The Geisinger Health Plan does not currently cover anti-obesity medications.  Health economist James Chambers at Tufts University says ‘…So now that you have these expensive drugs, it's not that surgeries become less expensive, but it does make you interpret the cost differently.’ Cristy Gallagher, at The STOP Obesity Alliance at the The George Washington University- Milken Institute School of Public Health , added ‘...you will not see a decrease in bariatric surgery in the near term, by any means.’ I agree wholeheartedly with Ted Kyle – it is not an either/or proposition – we need to think of it as the right treatment for the right patient at the right time – just as we take care of patients with cancer – radiotherapy, chemotherapy and surgery are all combined to achieve cure. We need to be bullish ‘…toward more integrated approaches to obesity…’ with surgery as a key tenet of care. https://lnkd.in/ec5p9TkU

Obesity management medications and metabolic bariatric surgery, better together 🤲 "Rather than viewing these highly effective and complementary treatment approaches as inevitable competitors, learning in whom, when, and how to combine them could be even more valuable and relevant to patient care." https://lnkd.in/euMk-jy2